Static Chart BioInvent International AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:30 2024-05-31 am EDT			5-day change	1st Jan Change
36.95 ^SEK	+10.13%		+12.14%	+94.88%

May. 23	BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors	CI
May. 23	BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024	CI

Duration

Period